SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kwality Pharmaceuticals Ltd (KPL)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539997 NSE: KPL Pharmaceuticals & Drugs | Small Cap | Kwality Pharma Share Price

₹2,497 124.25 (5.24%)

As on 12-Jun'26 16:59

Kwality Pharmaceuticals Ltd (KPL)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539997 NSE: KPL Pharmaceuticals & Drugs | Small Cap | Kwality Pharma Share Price

₹2,497 124.25 (5.24%)

As on 12-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹2,591 Cr.
Current Price
₹2,497
52-Week Low / High
₹829 / 2,600
TTM EPS
₹64.9
TTM Sales
₹503 Cr.
Book Value per Share
₹320.5
P/E Ratio
38.47
Higher than its 5-year historical median
Industry PE
47.2
Price to Book (P/B)
7.79
Higher than its 5-year historical median
Price to Sales (P/S)
5.15
Higher than its 5-year historical median
EV/EBITDA
22.45
Higher than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
16.28%
Outperforms industry median
Return on Capital Employed (ROCE)
18.30%
Outperforms industry median
Return on Assets (ROA)
9.42%
Operating Profit Margin
21.7%
Net Profit Margin
10.78%
Gross Profit Margin
19.6%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
20.52%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
20.73%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
66.35%
Asset Quality
Promoter Holding
54.87%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹322 Cr.
Equity
₹10.4 Cr.
Face Value
₹10
All Time Low / High
₹20.43 / 2600.00

Kwality Pharmaceuticals stock performance

Key Ratios
mw4me loader

Check Before You Invest

Quality

Somewhat Good

Valuation

Overvalued

Price Trend

Weak
Q.1 Is Kwality Pharmaceuticals Ltd a good quality company?
Kwality Pharmaceuticals Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Kwality Pharmaceuticals Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Kwality Pharmaceuticals Ltd vs industry peers?
Kwality Pharmaceuticals Ltd revenue CAGR is 21.70%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Kwality Pharmaceuticals Ltd?
Promoters hold 54.87% of the Kwality Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Kwality Pharmaceuticals Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 83.79% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Kwality Pharmaceuticals Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 14%19.5%19.4%21.5%18.5%26.5%97.2%12.3%13.6%18.3%-
Value Creation
Index
-00.40.40.50.30.95.9-0.10.00.3-

Growth Parameters

Sales 75.995.3137165139262456251307370503
Sales YoY Gr.-25.6%43.6%20.7%-16%88.6%74.4%-45%22.4%20.5%-
Adj EPS 2.13.74.57.3814.6114.62927.938.464.9
YoY Gr.-73.8%19.9%63%9.4%83.9%683.7%-74.7%-3.8%37.4%-
BVPS (₹) 21.624.629.236.544.659.5175.2193.9217255.4320.5
Adj Net
Profit
2.23.94.67.58.315.211930.12939.867
Cash Flow from Ops. -2.64-0.1135.626.459.242.243.452.8-
Debt/CF from Ops. -54.7-275.32.26.21.60.92.12.32.1-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales 19.3%21.7%-6.7%20.5%
Adj EPS 37.8%37%-30.6%37.4%
BVPS31.6%41.8%13.4%17.7%
Share Price - 87.8% 105% 142.7%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
10.215.816.121.619.227.79715.713.516.222.5
Op. Profit
Mgn %
7.69.68.49.210.211.237.724.321.721.723.5
Net Profit
Mgn %
2.84.13.44.665.826.1129.410.813.4
Debt to
Equity
0.60.70.90.70.80.70.30.50.40.40.1
Working Cap
Days
139157155154203126129319276265123
Cash Conv.
Cycle
6978696378363314115115156

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales7695137165139262456251307370
Operating Expenses + 7087125150125232284190241290
Manufacturing Costs458781379639395
Material Costs5870102119871661426990116
Employee Cost 2458111419283041
Other Costs 681116193944302838
Operating Profit 5911151429172616780
Operating Profit Margin (%) 7.1%9.0%8.4%9.2%10.2%11.2%37.6%24.3%21.7%21.7%
Other Income + 1211424322
Exceptional Items 0000000-17-70
Interest 122233371010
Depreciation 22334611152018
Profit Before Tax 368111122162263154
Tax 123336426714
Profit After Tax 2358815120192440
PAT Margin (%) 2.5%3.6%3.4%4.6%6.1%5.9%26.3%7.8%7.8%10.8%
Adjusted EPS (₹)1.93.34.57.38.114.9115.718.823.138.4
Dividend Payout Ratio (%)0%9.10%0%0%0%0%0%0%0%0%

Valuation of Kwality Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 232631394763183202226266
Share Capital 551010101010101010
Reserves 182121283752172192216255
Debt +12182526313543788698
Long Term Debt3347101820272015
Short Term Debt10152119211623516683
Minority Interest0000000000
Trade Payables10132217232635354456
Others Liabilities 8151926334582414229
Total Liabilities 527298107134169343357398449

Fixed Assets

Net Fixed Assets +11141522425691120138144
Gross Block212731406181127169205230
Accumulated Depreciation10121518202536496785
CWIP 014603121400
Investments 5798894444
Inventories9141511221753867883
Trade Receivables2023373930387173116156
Cash Equivalents 121015116514
Others Assets 71117203141101535647
Total Assets 527298107134169343357398449

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + -34-01362659424353
PBT 368111122162263154
Adjustment 34556914213728
Changes in Working Capital -7-4-91-92-752-23-14
Tax Paid -1-2-3-3-3-6-41-6-1-16
Cash Flow From Investing Activity + -2-7-6-12-17-23-63-48-26-28
Capex -2-7-6-12-18-23-55-46-26-25
Net Investments -0-1-0-11-0-0000
Others 001100-8-3-1-4
Cash Flow From Financing Activity + 555-212161-17-14
Net Proceeds from Shares 2100000000
Net Proceeds from Borrowing 211331097-7-5
Interest Paid -1-2-2-2-2-3-3-6-10-10
Dividend Paid 0-000000000
Others 356-312-70000
Net Cash Flow 01-1-1142-5-010

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)9.314.5816.7622.1720.0528.5598.6110.1711.2516.28
ROCE (%)13.9819.5119.3721.4718.5326.5197.1912.2813.6218.3
Asset Turnover Ratio1.681.531.611.611.151.721.780.720.810.87
PAT to CFO Conversion(x)-1.51.33-01.630.751.730.492.211.791.33
Working Capital Days
Receivable Days69.4081.4079.8083.9090.9047.5043.40104.70112.50134
Inventory Days36.3042.8038.2028.9044.3027.8028.30101.6097.9079.80
Payable Days43.2058.7062.2059.6083.9054.2078.10183.20161.90157.20

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Kwality Pharmaceuticals Ltd FAQs

The current trading price of Kwality Pharma on 12-Jun-2026 16:59 is ₹2,497.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 11-Jun-2026 the market cap of Kwality Pharma stood at ₹2,590.9 Cr

The latest P/E ratio of Kwality Pharma as of 11-Jun-2026 is 38.47.

The latest P/B ratio of Kwality Pharma as of 11-Jun-2026 is 7.79.

The 52-week high of Kwality Pharma is ₹2,600 and the 52-week low is ₹828.8.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kwality Pharma is ₹503 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Kwality Pharmaceuticals Ltd is a average quality company.

The key valuation ratios of Kwality Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kwality Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Kwality Pharmaceuticals Ltd

The company ‘Kwality Pharmaceuticals Limited’ was incorporated on May 04, 1983 vide Certificate of Incorporation issued by the Registrar of Companies, Punjab, H.P. and Chandigarh. It is engaged in the business of manufacturing of broad range of finished pharmaceutical formulations in a dosage form. It carries out its production through state-of-the-art manufacturing units situated at 6th Mile Stone, Village Nag Kalan, Majitha Road, Amritsar - 143006, Punjab, which is also its registered/administrative office and another manufacturing facility situated at 1-A Industrial Area, Raja ka bagh, Jassur, Himachal Pradesh. Both of its manufacturing facilities are well equipped and multiple products are manufactured at these facilities. Since incorporation, the company is ever progressing in Domestic and International market based on its commitment towards high quality and timely supplies. It provides specified and quality products for its customers while maintaining honesty, integrity and loyalty to its employees and customers.

The company has the most modern & sophisticated plant, equipments, technique and manpower. The company is ISO-9001:2000 and ISO 14001:2004 certified, and it is working with new SCHEDULE M and W.H.O. norms and certified with GMP and WHO certificate. The company’s production is based on standards laid down in pharmacopeia and technical reports series (TRS) guidelines of WHO (world health organization). 

Milestones

  • 1983: Incorporation of the company on May 04, 1983.
  • 2007: Received ISO Certification.
  • 2008: Commencement of new manufacturing unit at Jassur in Himachal Pradesh.
  • 2009: Received status of Star Export House Certificate.
  • 2012: Turnover increased by 75%.
  • 2013: Incorporation of Subsidiary Company in Africa.
  • 2014: Received WHO certification.
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: